<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of Crohn disease after surgical resection</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of Crohn disease after surgical resection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of Crohn disease after surgical resection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert M Penner, BSc, MD, FRCPC, MSc</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sunanda V Kane, MD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5501037"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Crohn disease (CD) is a chronic inflammatory bowel disease that results in significant morbidity and economic burden [<a href="#rid1">1,2</a>]. Although advances in medical therapy have coincided with lower rates of surgical resection in patients with CD, surgical intervention is often required in the setting of bowel obstruction, abscesses or fistulas, or refractory disease. The 10-year risk of surgical resection for CD is nearly 50 percent [<a href="#rid3">3</a>]. </p><p>While surgery often leads to clinical remission of CD, most patients ultimately relapse. The risk and severity of recurrence after surgical resection is variable and needs to be balanced with the potential risk of preventative medical therapy [<a href="#rid4">4</a>].</p><p>This topic will discuss the management of patients with CD following surgical resection. The American Gastroenterological Association has published guidelines on the management of CD after surgery, the contents of which are reflected in the subsequent discussions [<a href="#rid5">5</a>]. Other aspects of the medical and surgical management of CD are discussed separately. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/86198.html" rel="external">"Surgical management of Crohn disease"</a>.)</p><p class="headingAnchor" id="H4114685753"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>Flow of intestinal contents through the neo-terminal ileum and surgical anastomosis plays a significant role in recurrence [<a href="#rid6">6,7</a>]. In one report, three patients with CD who had undergone ileocolonic resection with ileocolonic anastomosis and temporary protective proximal loop ileostomy had no evidence of ileitis at six months after resection [<a href="#rid6">6</a>]. However, infusion of the ileostomy contents into the bypassed ileal segment for seven days resulted in morphologic evidence of focal inflammation on ileal biopsy. Thus, intestinal contents including bile salts, digestive enzymes, bacteria, and dietary antigens may trigger the postoperative recurrence of ileal CD within the first days after surgery. These findings suggest that in select patients, medical therapy should begin soon after resection and ileocolonic anastomosis are performed and continued indefinitely. (See <a class="local">'Higher-risk patients'</a> below.) </p><p class="headingAnchor" id="H2025966911"><span class="h1">POSTOPERATIVE RECURRENCE RATES</span><span class="headingEndMark"> — </span>Surgery does not cure CD. Although clinical remission is often achieved, most patients eventually relapse. Recurrent disease can manifest by histologic or endoscopic findings or with clinical symptoms. Many patients will require subsequent surgery. </p><p class="headingAnchor" id="H3486415734"><span class="h2">Histologic recurrence</span><span class="headingEndMark"> — </span>The earliest form of recurrence detection is by histology. In one series of three patients examined within eight days after surgical resection, histopathology revealed induction of inflammatory cells and markers in ileal mucosa in all patients [<a href="#rid6">6</a>]. </p><p class="headingAnchor" id="H2456199289"><span class="h2">Clinical recurrence</span><span class="headingEndMark"> — </span>Clinical recurrence rates range from 20 to 37 percent at one year and from 34 to 86 percent at three years [<a href="#rid8">8</a>]. Postoperative intervention trials showed clinical recurrence rates of 25 percent within two years [<a href="#rid9">9,10</a>]. A meta-analysis of the rates of clinical relapse in CD patients who were not receiving postoperative medical therapy found that the rates were 24 percent [<a href="#rid11">11</a>]. A meta-analysis of studies of patients with medically refractory CD who underwent any form of colectomy with permanent end ileostomy reported a clinical recurrence rate of 28 percent (95% CI, 22-35 percent) [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/86198.html" rel="external">"Surgical management of Crohn disease", section on 'Surgical techniques'</a>.)</p><p class="headingAnchor" id="H2707207495"><span class="h2">Endoscopic recurrence</span><span class="headingEndMark"> — </span>Rates of endoscopic recurrence are higher than clinical recurrence and may reach 70 to 90 percent at one year [<a href="#rid13">13,14</a>]. A meta-analysis of the rates of severe endoscopic recurrence in CD patients who were not receiving postoperative medical therapy found that the rates were 50 percent [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H100934520"><span class="h2">Surgical recurrence</span><span class="headingEndMark"> — </span>The need for a second operation defines surgical recurrence. In a meta-analysis of 12 studies, the 5-year and 10-year rates of reoperation were 24 percent (95% CI 23-26) and 35 percent (95% CI 32-39 percent), respectively [<a href="#rid15">15</a>]. A meta-analysis of studies of patients with medically refractory CD who underwent any form of colectomy with permanent end ileostomy reported an overall surgical recurrence rate of 16 percent (95% CI, 11-23 percent) [<a href="#rid12">12</a>].</p><p>Surgical intervention for CD often results in an ileocolic anastomosis and neo-terminal ileum, which is frequently the site of recurrence [<a href="#rid13">13</a>]. The common indications for subsequent surgery are similar to that for initial surgery: failure of medical treatment, bowel obstruction or perforation, fistulae and abscesses [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/86198.html" rel="external">"Surgical management of Crohn disease", section on 'Surgical approaches'</a>.) </p><p class="headingAnchor" id="H745310962"><span class="h2">Late recurrence</span><span class="headingEndMark"> — </span>Patients with initial endoscopic remission remain at risk for developing late recurrence (ie, disease recurrence beyond one year after surgery). In a study including 86 patients with history of ileocecal resection for CD and no recurrence at baseline postoperative colonoscopy, 35 patients (41 percent) had late recurrence with a median time to recurrence after baseline colonoscopy of 14 months (interquartile range 6 to 25 months) [<a href="#rid17">17</a>]. Disease recurrence was defined as a composite endpoint of at least one of the following: clinical recurrence, IBD-related hospitalization, bowel complication (eg, fistula), balloon dilation of the anastomosis, or repeat surgery. However, no risk factors for late postoperative recurrence were identified. This study supports continuing endoscopic surveillance for patients without recurrence at baseline colonoscopy after surgery. (See <a class="local">'Lower-risk patients'</a> below.)</p><p class="headingAnchor" id="H3876409795"><span class="h1">RISK FACTORS FOR RECURRENCE</span><span class="headingEndMark"> — </span>Identification of risk factors for recurrence can help determine if the patient should begin medical therapy soon after surgery (ie, two to eight weeks postoperatively) or if the patient can be monitored for disease recurrence. (See <a class="local">'Risk stratification'</a> below.)</p><p>Risk factors can be classified as patient-, disease- or surgery-related.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient-related risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Smoking</strong> – Several studies have suggested that smoking increases the risk of clinical, endoscopic, and surgical recurrence [<a href="#rid18">18-21</a>]. A meta-analysis of 16 studies demonstrated that smokers have higher rates of both postoperative clinical recurrence (OR 2.2, 95% CI 1.4-3.3) and surgical recurrence (OR 2.6, 95%CI 1.8-3.8) at 10 year follow-up [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/4066.html" rel="external">"Definitions, epidemiology, and risk factors for inflammatory bowel disease", section on 'Smoking'</a> and <a class="local">'Smoking cessation'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetics</strong> – Whether genetic factors predict disease recurrence has not been well studied. One report found that patients with the NOD2/CARD15 mutation had a higher rate of postoperative recurrence and required surgery earlier compared with patients without the mutation [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/4077.html" rel="external">"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease", section on 'Genetic susceptibility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease-related risk factors</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease duration</strong> – Shorter preoperative disease duration is associated with an increased rate of recurrence [<a href="#rid24">24,25</a>]. One study showed that the risk of recurrence at five years was greater for patients with CD duration of less than 10 years compared with CD duration of greater than 10 years (65 versus 23 percent) [<a href="#rid24">24</a>]. The relative risk for recurrence was 1.5 for patients with disease for two years versus 10 years prior to the initial surgery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease extent</strong> – The presence of proximal gastrointestinal (duodenum or jejunum) and diffuse disease that involves the colon has been associated with clinical and endoscopic recurrence [<a href="#rid26">26-29</a>]. In a population based cohort study, patients with disease involving the small bowel or continuous ileocolonic disease were at increased risk for recurrence compared with patients with only colonic involvement (OR 1.8, 95% CI 1.2-1.6, and OR 1.5, 95%CI 1.1-2.0, respectively) [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Prior surgery for CD</strong> – While the number of surgeries has not been systematically studied as a risk factor for postoperative recurrence of CD, it is conventionally listed as a risk factor [<a href="#rid29">29,30</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Penetrating or fistulizing disease</strong> – A meta-analysis demonstrated that postoperative patients with perforating or fistulizing CD were more likely to have recurrence that required reoperation compared with patients with nonperforating CD (HR 1.5, 95% CI, 1.2-1.9) [<a href="#rid30">30</a>]. One study suggested an increased risk of recurrence in patients with fistulizing disease (OR 4.1, 95%CI 1.3-12.7) [<a href="#rid31">31</a>]. In general, patients with a history of fistula have a worse prognosis [<a href="#rid32">32</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stricturing disease</strong> – Short stricturing disease is considered lower risk for recurrence compared with fistulizing or penetrating disease. One series found that recurrence after conservative surgery, which included small bowel resections and strictureplasty, was more likely in younger patients (HR 2.4, 95%CI 1-5.4) and in the setting of stricturing disease (HR 2.2, 95%CI 1.1-4.1) [<a href="#rid33">33</a>]. Another series found no cases of recurrence within three years in 12 patients with stricturing disease compared with 12 of 22 patients (55 percent) who had penetrating disease [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgery-related risk factors</strong> – Surgical technique can affect the risk of recurrence. Side to side anastomosis of an ileocolic resection is associated with lower recurrence rates compared with end to end anastomosis [<a href="#rid35">35</a>]. The presence of an ileorectal anastomosis following colectomy is associated with a higher recurrence rate (58 percent) at 10 years compared with the creation of an end ileostomy following both proctocolectomy (37 percent) and subtotal colectomy (24 percent) [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/d/html/86198.html" rel="external">"Surgical management of Crohn disease", section on 'Anastomotic technique'</a>.)</p><p></p><p class="headingAnchor" id="H5501044"><span class="h1">POSTOPERATIVE MONITORING</span><span class="headingEndMark"> — </span>The presentation of postoperative CD follows a natural progression from histologic to endoscopic to clinical and finally, to surgical recurrence [<a href="#rid37">37</a>]. Thus, endoscopic monitoring may allow earlier diagnosis of recurrence, earlier treatment, and better prognosis.</p><p class="headingAnchor" id="H5501051"><span class="h2">Ileocolonoscopy</span><span class="headingEndMark"> — </span>Endoscopic recurrence precedes clinical recurrence, providing an opportunity for medical intervention prior to development of symptoms or complications. We recommend an ileocolonoscopy 6 to 12 months following surgery in all patients, including those who are receiving postoperative medical therapy. </p><p>The benefit of endoscopic monitoring, even in the setting of postoperative medical prophylaxis, has been demonstrated. A randomized clinical trial of 174 postoperative patients receiving at least one prophylactic medication evaluated the outcome of endoscopic assessment (ie, ‘active management’) at six months versus no endoscopic monitoring [<a href="#rid38">38</a>]. If endoscopic recurrence was identified at six months, step up therapy was provided. At 18 months, endoscopic recurrence was detected less frequently in the active management group versus the group without endoscopic monitoring (49 versus 67 percent). The risk, cost, and burden (ie, possible discomfort, need for bowel preparation, time away from work or school) of colonoscopy should be balanced with the benefit of lowering the risk of recurrent CD by initiating or adjusting therapy based on the endoscopic assessment. (See  <a class="medical medical_review" href="/d/html/13927.html" rel="external">"Overview of colonoscopy in adults", section on 'Adverse events'</a>.) </p><p>An endoscopic scoring system predicts clinical recurrence based on the endoscopic findings [<a href="#rid13">13,39,40</a>]. The neo-terminal ileum is assessed during the initial postoperative endoscopy and scored by the following scale:</p><p class="bulletIndent1"><span class="glyph">●</span>i0: no lesions, normal appearing neo-terminal ileum</p><p class="bulletIndent1"><span class="glyph">●</span>i1: &lt;5 aphthous ulcers in the neo-terminal ileum</p><p class="bulletIndent1"><span class="glyph">●</span>i2: &gt;5 aphthous ulcers in the neo-terminal ileum with normal intervening mucosa</p><p class="bulletIndent1"><span class="glyph">●</span>i3: diffuse aphthous ileitis with diffusely inflamed mucosa</p><p class="bulletIndent1"><span class="glyph">●</span>i4: diffuse inflammation with large ulcers, nodules and/or narrowing.</p><p></p><p>Endoscopic remission is defined as a score of i0 or i1; less than 5 percent of these patients progress to clinical recurrence at three years [<a href="#rid13">13,39</a>]. Endoscopic recurrence is defined as a score of i2, i3 or i4, and patients with an endoscopic score of i3 or i4 were most likely to develop clinical relapse and have significant progressive disease requiring medical or surgical intervention.</p><p>Whether the severity of endoscopic findings correlates with the clinical course is uncertain. While some studies have found that severe radiologic or endoscopic findings (such as stricture, deep ulceration, cobblestoning, or fistulization) predicted symptomatic recurrence, others have shown poor correlation between symptoms, endoscopy, and repeat surgery [<a href="#rid13">13,41-44</a>].</p><p class="headingAnchor" id="H5501058"><span class="h2">Clinical follow-up</span><span class="headingEndMark"> — </span>Patients are followed closely for development of clinical symptoms which prompt further evaluation and initiation of or step up of medical therapy. Clinical recurrence is based upon signs and symptoms of disease. </p><p>We obtain fecal calprotectin and C-reactive protein as surrogate, noninvasive markers of disease activity at six month intervals for two years after surgery and annually thereafter. An abnormal fecal calprotectin is usually followed up with colonoscopy after which medications can be adjusted accordingly. (See <a class="local">'Higher-risk patients'</a> below and  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Health maintenance'</a>.)</p><p>Measuring fecal lactoferrin, another noninvasive marker, is an alternative to fecal calprotectin. We typically measure the stool marker that correlated well with the patient's disease activity preoperatively, if that information is available. In addition, CT or magnetic resonance (MR) enterography may complement the endoscopic evaluation for patients with postsurgical anatomy that limits visualization of neoterminal ileum or with disease involving the more proximal small bowel.</p><p>The Crohn disease activity index (CDAI) has been used to provide a more objective measure of clinical activity, although the CDAI is not a highly reliable instrument in the postoperative setting (<a class="calc calc_professional" href="/d/html/15646.html" rel="external">calculator 1</a>). (See <a class="local">'Clinical recurrence'</a> above.) </p><p class="headingAnchor" id="H92678090"><span class="h1">MEDICAL PROPHYLAXIS</span><span class="headingEndMark"> — </span>Prevention of postoperative recurrence of CD requires determining which patients will benefit from early medical therapy and which patients should be monitored clinically, thereby avoiding the risks of therapy (<a class="graphic graphic_algorithm graphicRef113707" href="/d/graphic/113707.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H2005621280"><span class="h2">Risk stratification</span><span class="headingEndMark"> — </span>Patients can be stratified into lower- and higher-risk groups based on risk factors [<a href="#rid40">40</a>]. (See <a class="local">'Risk factors for recurrence'</a> above.)</p><p class="headingAnchor" id="H3772650234"><span class="h3">Lower-risk patients</span><span class="headingEndMark"> — </span>Patients with the following characteristics are at lower risk for recurrence:</p><p class="bulletIndent1"><span class="glyph">●</span>Nonsmokers</p><p class="bulletIndent1"><span class="glyph">●</span>Older patients (age over 50 years) </p><p class="bulletIndent1"><span class="glyph">●</span>First operation for CD</p><p class="bulletIndent1"><span class="glyph">●</span>Short stricturing CD (ie, less than 10 to 20 cm)</p><p class="bulletIndent1"><span class="glyph">●</span>Long standing history of CD (greater than 10 years)</p><p></p><p>Because of the potential for adverse effects of long-term immunosuppressive therapy, we reserve its use for patients at higher risk of disease recurrence. (See <a class="local">'Higher-risk patients'</a> below.)</p><p>We suggest a three month course of imidazole antibiotic therapy (ie, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) for lower-risk patients, if there are no contraindications (<a class="graphic graphic_algorithm graphicRef113707" href="/d/graphic/113707.html" rel="external">algorithm 1</a>). Some lower-risk patients may decline a course of antibiotics, and an alternative approach is to monitor these patients clinically, particularly in the setting of intolerance to metronidazole [<a href="#rid29">29,45</a>]. (See <a class="local">'Antibiotics'</a> below and <a class="local">'General care for patients after surgery'</a> below.)</p><p>At 6 to 12 month follow-up, these patients undergo ileocolonoscopy. If endoscopic recurrence is found, medical therapy is recommended as discussed in the following section. (See <a class="local">'Medications'</a> below and <a class="local">'Higher-risk patients'</a> below.) </p><p>If the ileocolonoscopy shows endoscopic remission, patients undergo subsequent surveillance colonoscopy in one to three years. </p><p>If lower-risk patients develop symptoms of CD recurrence prior to follow-up colonoscopy, we suggest an evaluation and treatment approach for flare of CD similar to that in patients who have not had surgery. </p><p class="headingAnchor" id="H4293300700"><span class="h3">Higher-risk patients</span><span class="headingEndMark"> — </span>The following characteristics are risk factors for recurrence:</p><p class="bulletIndent1"><span class="glyph">●</span>Lack of response to biologic therapy prior to surgery</p><p class="bulletIndent1"><span class="glyph">●</span>Tobacco use</p><p class="bulletIndent1"><span class="glyph">●</span>Patients younger than age 30 years </p><p class="bulletIndent1"><span class="glyph">●</span>Perforating/penetrating/fistulizing/long segment inflammatory disease </p><p class="bulletIndent1"><span class="glyph">●</span>History of ≥2 surgeries for CD </p><p class="bulletIndent1"><span class="glyph">●</span>Shorter disease duration prior to surgery</p><p></p><p>Individual risk factors may have different impact on prognosis; thus, while tobacco use would be considered higher risk for disease recurrence following surgery, shorter duration of disease prior to surgery might be considered a high-risk feature only in combination. Despite the identification of risk factors, optimal approaches and patient selection have not been clearly defined. The risks and benefits of each medical treatment, the baseline risk of recurrence, individual patient preferences and cost all warrant careful consideration and a shared decision-making approach is recommended.</p><p>For most patients at higher risk, we initiate postoperative immunosuppressive therapy with an anti-TNF agent alone or in combination with an immunomodulator (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>). An anti-TNF agent is first-line biologic therapy for most patients in this setting. However, for nonresponders to preoperative anti-TNF therapy (ie, patients who required surgical resection for active inflammation), we switch to a different biologic agent or we escalate the previous drug regimen by optimizing the dose or adding an immunomodulator. In contrast, patients who undergo resection of fibrotic strictures without active inflammation usually resume the same medical regimen after surgery. </p><p>For patients who cannot tolerate anti-TNF therapy postoperatively because of infectious complications, a three-month course of imidazole antibiotic therapy (ie, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) is an option for short-term prophylaxis until biologic therapy can be safely administered. (See <a class="local">'Lower-risk patients'</a> above.)</p><p>The efficacy and safety of anti-TNF therapy alone or in combination with an immunomodulator are discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a> and  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a>.)</p><p>Medication adjustments for patients with loss of response to anti-TNF agents are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors", section on 'Patients with active disease despite maintenance therapy'</a>.) </p><p>Data from clinical trials suggested that postoperative therapy with an anti-TNF agent or an immunomodulator reduced the risk of clinical recurrence. (See <a class="local">'Anti-tumor necrosis factor agents'</a> below and <a class="local">'Immunomodulators'</a> below.)</p><p>While the use of immunosuppressive therapy in the postoperative period may be a concern, a review of perioperative safety profiles of drugs commonly administered for CD found evidence of adverse effects on wound healing only for glucocorticoids, but not for anti-TNF agents or immunomodulators [<a href="#rid46">46</a>]. </p><p>Ileocolonoscopy is performed at 6 to 12 months and if endoscopic recurrence is found despite medical therapy, treatment can be intensified with the following options:</p><p class="bulletIndent1"><span class="glyph">●</span>Increasing the dose of the anti-TNF agent, guided by therapeutic drug monitoring</p><p class="bulletIndent1"><span class="glyph">●</span>Adding an immunomodulator (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) to the anti-TNF regimen, if not done previously, or</p><p class="bulletIndent1"><span class="glyph">●</span>Switching to a different biologic agent (eg, anti-IL 12/23 agent)</p><p></p><p>If the ileocolonoscopy at 6 to 12 months after surgery shows no endoscopic recurrence (ie, Rutgeerts score i0 or i1), the patient can be monitored clinically on this regimen and surveillance ileocolonoscopy is performed in one to three years [<a href="#rid40">40</a>]. (See <a class="local">'General care for patients after surgery'</a> below.)</p><p class="headingAnchor" id="H3616997213"><span class="h2">Medications</span></p><p class="headingAnchor" id="H2527583845"><span class="h3">Anti-tumor necrosis factor agents</span><span class="headingEndMark"> — </span>Data from clinical trials suggested that prophylaxis with an anti-TNF agent reduced the risk of both clinical and endoscopic recurrence following surgical resection compared with no prophylaxis (OR 0.51, 95% CI 0.28-0.94, and OR 0.24, 95% CI 0.15-0.39, respectively) [<a href="#rid29">29,47,48</a>]. In addition, in an analysis of individual patient data from six trials including 645 participants, postoperative use of an anti-TNF agent resulted in lower risk of clinical and endoscopic recurrence compared with thiopurine monotherapy (relative risk [RR] 0.50, 95% CI 0.26-0.96 and RR 0.52, 95% CI 0.33-0.80, respectively) [<a href="#rid49">49</a>]. </p><p>The risk of adverse effects must be weighed against the potential benefits of anti-TNF agents as the use of anti-TNF prophylaxis results in endoscopic recurrence rates ranging from 10 to 20 percent after one year [<a href="#rid49">49-51</a>]. In two trials of anti-TNF agents in CD patients after surgical resection, there were no differences in adverse event rates (including infection rates) in the anti-TNF group versus either the placebo or immunomodulator groups [<a href="#rid47">47,52</a>]. Adverse effects of these agents are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/4078.html" rel="external">"Treatment of Crohn disease in adults: Dosing and monitoring of tumor necrosis factor-alpha inhibitors"</a> and  <a class="medical medical_review" href="/d/html/7970.html" rel="external">"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"</a> and <a class="local">'Infection risk'</a> below.)</p><p class="headingAnchor" id="H3251525188"><span class="h4">Infliximab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">Infliximab</a> has been demonstrated to lower endoscopic and possibly clinical recurrence rates in postoperative CD. In a randomized study (PREVENT trial) of 297 patients with postsurgical CD, endoscopic recurrence rates before or at week 76 were lower in patients receiving infliximab compared with placebo (31 versus 60 percent, absolute risk reduction with infliximab, 29.4 percent; 95% CI: 18.6 to 40.2) [<a href="#rid47">47</a>]. Clinical recurrence rates were also reduced but the difference was not statistically significant (13 versus 20 percent), absolute risk reduction with infliximab 7.1 percent (95% CI: -1.3 to 15.5). These results were similar to those in a previous smaller trial [<a href="#rid48">48</a>]. In an open label, follow-up study of the smaller trial, patients were given the option to continue, stop, or start infliximab [<a href="#rid53">53</a>]. At five years, endoscopic recurrence was higher in patients who had not used infliximab compared with those who had (96 percent versus 22 percent), suggesting a long-term benefit of infliximab. </p><p class="headingAnchor" id="H3458965157"><span class="h4">Adalimumab</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">Adalimumab</a> also appears effective in preventing endoscopic and clinical recurrence in patients with CD [<a href="#rid52">52,54-56</a>]. In a randomized trial, 51 patients with CD were assigned to receive adalimumab, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>, or <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> two weeks after ileocolonic resection [<a href="#rid54">54</a>]. At two-year follow-up, endoscopic recurrence rates were significantly lower in patients treated with adalimumab as compared with azathioprine and mesalamine (6, 65, and 83 percent, respectively). In addition, a significantly lower proportion of patients treated with adalimumab experienced clinical recurrence as compared with patients treated with azathioprine or mesalamine (13, 65, and 50 percent, respectively). (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.)</p><p>Limited data from retrospective studies suggest that <a class="drug drug_general" data-topicid="8984" href="/d/drug information/8984.html" rel="external">infliximab</a> and <a class="drug drug_general" data-topicid="8583" href="/d/drug information/8583.html" rel="external">adalimumab</a> have similar efficacy for the prevention of postoperative recurrence of CD [<a href="#rid57">57,58</a>].</p><p class="headingAnchor" id="H3540837433"><span class="h3">Other biologics</span><span class="headingEndMark"> — </span>Evidence is lacking for biologic agents with other mechanisms of action in the postoperative setting. <a class="drug drug_general" data-topicid="9514" href="/d/drug information/9514.html" rel="external">Ustekinumab</a>, <a class="drug drug_general" data-topicid="121112" href="/d/drug information/121112.html" rel="external">risankizumab</a>, and <a class="drug drug_general" data-topicid="95501" href="/d/drug information/95501.html" rel="external">vedolizumab</a> have each demonstrated efficacy in other clinical contexts, but their role in postoperative maintenance is not yet clear. We reserve the use of ustekinumab, risankizumab, or vedolizumab for patients who have failed anti-TNF therapy or in whom we are restricted by specific contraindications to anti-TNF agents that do not impact use of other biologic agents. (See  <a class="medical medical_review" href="/d/html/16224.html" rel="external">"Medical management of moderate to severe Crohn disease in adults"</a>.) </p><p class="headingAnchor" id="H5501100"><span class="h3">Immunomodulators</span><span class="headingEndMark"> — </span>Postoperative therapy with an immunomodulator (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a> [AZA], <a class="drug drug_general" data-topicid="9612" href="/d/drug information/9612.html" rel="external">6-mercaptopurine</a> [6-MP]) resulted in decreased risk of clinical recurrence according to a meta-analysis of three trials including 408 patients who had undergone surgery for CD and were followed for one to three years [<a href="#rid59">59</a>]. Compared with placebo, patients treated with AZA/6-MP had a lower risk of clinical recurrence (RR 0.79, 95% CI 0.67-0.92), while the risk of endoscopic recurrence was not significantly lower (RR 0.85, 95% CI 0.64-1.13). The rates of adverse effects were not significantly different for patients treated with AZA/6-MP compared with placebo (14 versus 10 percent) [<a href="#rid59">59</a>].</p><p>The benefit of AZA may be increased by combining it with a three month course of <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid60">60,61</a>]. In one trial, rates of endoscopic recurrence were lower in patients on metronidazole for three months and AZA for 12 months versus metronidazole alone for three months (44 versus 69 percent). (See <a class="local">'Antibiotics'</a> below.)</p><p class="headingAnchor" id="H3665036036"><span class="h3">Antibiotics</span><span class="headingEndMark"> — </span>Treatment with antibiotics is generally safe but side effects may limit their use. Studies have shown that disease recurrence develops only when the mucosa is re-exposed to luminal contents, thus indicating that bacteria may have a role in recurrence; this provides a rationale for the use of antibiotics [<a href="#rid6">6,7</a>]. </p><p>Data suggest a modest benefit from the short-term use of nitroimidazole antibiotics in preventing postoperative recurrence during the first year after resection in patients with ileal or ileocolonic disease [<a href="#rid9">9,29,62,63</a>]. A summary of three trials of antibiotic therapy (2-metronidazole; 1-ciprofloxacin) showed an uncertain but potentially substantial reduction in clinical recurrence and endoscopic recurrence (OR 0.52, CI 95% 0.27-1.02 and OR 0.46, CI 95% 0.21-0.99, respectively) [<a href="#rid29">29</a>]. In a trial of 60 patients with CD after ileal resection, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> therapy compared with placebo resulted in a lower rate of total (52 versus 75 percent) and severe (13 versus 43 percent) endoscopic recurrence at three months and a lower clinical recurrence rate at one year (4 versus 25 percent) [<a href="#rid9">9</a>]. The majority of study dropouts were due to a metallic taste and gastrointestinal upset. Paresthesias and peripheral neuropathy were self-limited after discontinuation of the drug and overall side effects were less common than have been reported with metronidazole use in other settings. (See  <a class="medical medical_review" href="/d/html/464.html" rel="external">"Metronidazole: An overview", section on 'Toxicity'</a>.)</p><p class="headingAnchor" id="H776148051"><span class="h3">Mesalamine</span><span class="headingEndMark"> — </span>Data suggest that <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> prophylaxis is associated with a modest benefit in preventing relapse. A meta-analysis of nine randomized controlled trials found that mesalamine agents were more effective than placebo for preventing relapse following surgery (OR 0.7, 95% CI, 0.5-0.9) [<a href="#rid64">64</a>]. The number needed to treat to prevent one recurrence was approximately 16 to 19. In the setting of quiescent CD, a meta-analysis of 13 randomized trials for maintenance of remission of CD showed no benefit of 5-ASA agents compared with placebo (relapse rate 56 versus 57 percent) [<a href="#rid65">65</a>]. (See  <a class="medical medical_review" href="/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p>A study of 206 patients compared the effect of high-dose <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> (4 grams daily) versus low dose (2.4 grams daily) with placebo for one year following resection. The rate of any endoscopic recurrence at one year was greater in the low-dose group than in the high-dose group (62 versus 46 percent), yet there was no significant difference in the rate of severe endoscopic recurrence between the two doses [<a href="#rid66">66</a>].</p><p>Although there remains uncertainty about its efficacy, <a class="drug drug_general" data-topicid="9614" href="/d/drug information/9614.html" rel="external">mesalamine</a> is generally safe and well-tolerated and, thus, it is a reasonable option in some patients. Such patients include those who appear to benefit from mesalamine prior to resection or those unwilling to consider agents with more side effects. (See <a class="local">'Infection risk'</a> below.) </p><p class="headingAnchor" id="H452760564"><span class="h1">GENERAL CARE FOR PATIENTS AFTER SURGERY</span></p><p class="headingAnchor" id="H4079989348"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>All patients with CD who use tobacco should receiving counseling in smoking cessation. Smoking is associated with higher risk of postoperative disease recurrence. (See  <a class="medical medical_review" href="/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a> and <a class="local">'Risk factors for recurrence'</a> above.)</p><p class="headingAnchor" id="H1703216482"><span class="h2">Health maintenance</span><span class="headingEndMark"> — </span>It is important to address health maintenance, including screening and prevention of other diseases as well as monitoring for side effects of therapy in patients with inflammatory bowel disease (IBD). A clinical guideline issued by the American College of Gastroenterology addresses preventive care in IBD and those recommendations are discussed separately. (See  <a class="medical medical_review" href="/d/html/4051.html" rel="external">"Medical management of low-risk adult patients with mild to moderate ulcerative colitis", section on 'Health maintenance'</a>.)</p><p class="headingAnchor" id="H764190121"><span class="h2">Screening for metabolic bone disease</span><span class="headingEndMark"> — </span>Osteoporosis is common in IBD and patients who are at risk for bone loss fracture can be identified through clinical evaluation which is discussed separately. (See  <a class="medical medical_review" href="/d/html/2028.html" rel="external">"Metabolic bone disease in inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H2743973090"><span class="h2">Infection risk</span><span class="headingEndMark"> — </span>Treatment with immunomodulators or biologics confers an increased risk of bacterial, fungal, and viral infection and infection risk is discussed separately. (See  <a class="medical medical_review" href="/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a> and  <a class="medical medical_review" href="/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a>.)</p><p class="headingAnchor" id="H2483882059"><span class="h2">Nutrition</span><span class="headingEndMark"> — </span>Nutritional status should be assessed in all patients with CD including those in postoperative remission. Nutritional assessment and interventions in adults with IBD are discussed separately. (See  <a class="medical medical_review" href="/d/html/13924.html" rel="external">"Nutrition and dietary management for adults with inflammatory bowel disease"</a>.)</p><p class="headingAnchor" id="H3914410486"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109856.html" rel="external">"Society guideline links: Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H92572021"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15383.html" rel="external">"Patient education: Crohn disease in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2004.html" rel="external">"Patient education: Crohn disease (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5501149"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – Surgery does not cure Crohn disease (CD). Although clinical remission is often achieved, most patients eventually relapse. Recurrent disease can manifest by histologic or endoscopic findings or with clinical symptoms. Many patients will require subsequent surgery. (See <a class="local">'Postoperative recurrence rates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for recurrence</strong> – Identification of risk factors for recurrence can help determine if the patient should begin medical therapy soon after surgery or if the patient can be monitored for disease recurrence. Smoking is a modifiable patient-related risk factor. Examples of disease-related risk factors for recurrence are a shorter disease duration prior to the initial operation, history of surgery for CD, and penetrating/fistulizing disease. (See <a class="local">'Risk factors for recurrence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postoperative monitoring</strong> – Endoscopic recurrence precedes clinical recurrence, providing an opportunity for medical intervention prior to development of symptoms or complications. We perform ileocolonoscopy 6 to 12 months following surgery in all patients, including those who are receiving postoperative medical therapy (<a class="graphic graphic_algorithm graphicRef113707" href="/d/graphic/113707.html" rel="external">algorithm 1</a>). (See <a class="local">'Ileocolonoscopy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive strategies:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Lower risk patients </strong>– For lower-risk patients, we suggest a three-month course of imidazole antibiotic therapy (ie, <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). An alternative approach is to monitor lower-risk patients clinically without prophylactic medical therapy initially, particularly in the setting of intolerance to metronidazole. (See <a class="local">'Risk stratification'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Higher-risk patients</strong> – For higher-risk patients, we suggest immunosuppressive prophylaxis after surgery (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>). We typically begin immunosuppressive prophylaxis within eight weeks after surgical resection. Postoperative therapy with an anti-tumor necrosis factor (TNF) agent alone or in combination with an immunomodulator (eg, <a class="drug drug_general" data-topicid="9026" href="/d/drug information/9026.html" rel="external">azathioprine</a>) reduces the risk of clinical recurrence. (See <a class="local">'Anti-tumor necrosis factor agents'</a> above.)</p><p></p><p class="bulletIndent2">For treatment-naive patients, we begin an anti-TNF-based regimen. </p><p></p><p class="bulletIndent2">For patients who had active bowel inflammation despite preoperative anti-TNF therapy, we switch to another biologic agent or escalate the previous anti-TNF regimen by increasing the dose or adding an immunomodulator. (See <a class="local">'Higher-risk patients'</a> above.) </p><p></p><p class="bulletIndent2">For patients with contraindications to postoperative anti-TNF therapy (eg, postsurgical infectious complications), a three-month course of <a class="drug drug_general" data-topicid="9646" href="/d/drug information/9646.html" rel="external">metronidazole</a> is an option for short-term prophylaxis until biologic therapy can be safely administered. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General measures</strong> – Routine health maintenance in the postoperative setting includes screening for other diseases and monitoring for side effects of therapy in patients with inflammatory bowel disease. All patients with CD who use tobacco should receive counseling in smoking cessation. (See <a class="local">'General care for patients after surgery'</a> above.)</p><p></p><p class="headingAnchor" id="H235523432"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Puneeta Tandon, MD and Richard Fedorak, MD (deceased), who contributed to earlier versions of this topic review.</p><p>The UpToDate editorial staff also acknowledges Paul Rutgeerts, MD (deceased), who contributed to earlier versions of this topic review and was a section editor for UpToDate in Gastroenterology.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98:1064.</a></li><li><a class="nounderline abstract_t">Wolters FL, Russel MG, Stockbrügger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20:483.</a></li><li><a class="nounderline abstract_t">Frolkis AD, Dykeman J, Negrón ME, et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013; 145:996.</a></li><li><a class="nounderline abstract_t">Ananthakrishnan AN. Surgery for Crohn's disease: look harder, act faster. Lancet 2015; 385:1370.</a></li><li><a class="nounderline abstract_t">Nguyen GC, Loftus EV Jr, Hirano I, et al. American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. Gastroenterology 2017; 152:271.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338:771.</a></li><li><a class="nounderline abstract_t">Swoger JM, Regueiro M. Evaluation for postoperative recurrence of Crohn disease. Gastroenterol Clin North Am 2012; 41:303.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617.</a></li><li><a class="nounderline abstract_t">Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000; 118:264.</a></li><li><a class="nounderline abstract_t">Renna S, Cammà C, Modesto I, et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008; 135:1500.</a></li><li><a class="nounderline abstract_t">Fumery M, Dulai PS, Meirick P, et al. Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther 2017; 45:381.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956.</a></li><li><a class="nounderline abstract_t">Olaison G, Smedh K, Sjödahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33:331.</a></li><li><a class="nounderline abstract_t">Frolkis AD, Lipton DS, Fiest KM, et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol 2014; 109:1739.</a></li><li><a class="nounderline abstract_t">Lightner AL, Vogel JD, Carmichael JC, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease. Dis Colon Rectum 2020; 63:1028.</a></li><li><a class="nounderline abstract_t">Pouillon L, Remen T, Amicone C, et al. Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers. Clin Gastroenterol Hepatol 2021; 19:1218.</a></li><li><a class="nounderline abstract_t">Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187:219.</a></li><li><a class="nounderline abstract_t">Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005; 11:3971.</a></li><li><a class="nounderline abstract_t">Cottone M, Orlando A, Modesto I. Postoperative maintenance therapy for inflammatory bowel disease. Curr Opin Gastroenterol 2006; 22:377.</a></li><li><a class="nounderline abstract_t">Papay P, Reinisch W, Ho E, et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol 2010; 105:1158.</a></li><li><a class="nounderline abstract_t">Reese GE, Nanidis T, Borysiewicz C, et al. The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies. Int J Colorectal Dis 2008; 23:1213.</a></li><li><a class="nounderline abstract_t">Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242:693.</a></li><li><a class="nounderline abstract_t">Sachar DB, Wolfson DM, Greenstein AJ, et al. Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology 1983; 85:917.</a></li><li><a class="nounderline abstract_t">Poggioli G, Laureti S, Selleri S, et al. Factors affecting recurrence in Crohn's disease. Results of a prospective audit. Int J Colorectal Dis 1996; 11:294.</a></li><li><a class="nounderline abstract_t">Raab Y, Bergström R, Ejerblad S, et al. Factors influencing recurrence in Crohn's disease. An analysis of a consecutive series of 353 patients treated with primary surgery. Dis Colon Rectum 1996; 39:918.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Gasparaitis AE, Hanauer SB. Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut 1995; 36:715.</a></li><li><a class="nounderline abstract_t">Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231:38.</a></li><li><a class="nounderline abstract_t">Regueiro M, Velayos F, Greer JB, et al. American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection. Gastroenterology 2017; 152:277.</a></li><li><a class="nounderline abstract_t">Simillis C, Yamamoto T, Reese GE, et al. A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease. Am J Gastroenterol 2008; 103:196.</a></li><li><a class="nounderline abstract_t">Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 2005; 72:248.</a></li><li><a class="nounderline abstract_t">Borley NR, Mortensen NJ, Chaudry MA, et al. Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. Dis Colon Rectum 2002; 45:377.</a></li><li><a class="nounderline abstract_t">Sampietro GM, Corsi F, Maconi G, et al. Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease. Clin Gastroenterol Hepatol 2009; 7:183.</a></li><li><a class="nounderline abstract_t">Sachar DB, Lemmer E, Ibrahim C, et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis 2009; 15:1071.</a></li><li><a class="nounderline abstract_t">Scarpa M, Ruffolo C, Bertin E, et al. Surgical predictors of recurrence of Crohn's disease after ileocolonic resection. Int J Colorectal Dis 2007; 22:1061.</a></li><li><a class="nounderline abstract_t">Bernell O, Lapidus A, Hellers G. Recurrence after colectomy in Crohn's colitis. Dis Colon Rectum 2001; 44:647.</a></li><li><a class="nounderline abstract_t">Ghosh S, D'Haens G. Is an Ounce of Prevention Worth a Pound of Cure: Postoperative Recurrence of Crohn's Disease? Gastroenterology 2016; 150:1521.</a></li><li><a class="nounderline abstract_t">De Cruz P, Kamm MA, Hamilton AL, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015; 385:1406.</a></li><li><a class="nounderline abstract_t">Blum E, Katz JA. Postoperative therapy for Crohn's disease. Inflamm Bowel Dis 2009; 15:463.</a></li><li><a class="nounderline abstract_t">Hashash JG, Regueiro M. A Practical Approach to Preventing Postoperative Recurrence in Crohn's Disease. Curr Gastroenterol Rep 2016; 18:25.</a></li><li><a class="nounderline abstract_t">McLeod RS, Wolff BG, Steinhart AH, et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 1997; 113:1823.</a></li><li><a class="nounderline abstract_t">Achkar JP, Shen B. Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence. Curr Gastroenterol Rep 2001; 3:484.</a></li><li><a class="nounderline abstract_t">Kotanagi H, Kramer K, Fazio VW, Petras RE. Do microscopic abnormalities at resection margins correlate with increased anastomotic recurrence in Crohn's disease? Retrospective analysis of 100 cases. Dis Colon Rectum 1991; 34:909.</a></li><li><a class="nounderline abstract_t">de Jong E, van Dullemen HM, Slors JF, et al. Correlation between early recurrence and reoperation after ileocolonic resection in Crohn's disease: a prospective study. J Am Coll Surg 1996; 182:503.</a></li><li><a class="nounderline abstract_t">De Cruz P, Kamm MA, Prideaux L, et al. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012; 18:758.</a></li><li><a class="nounderline abstract_t">Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 2005; 25:1566.</a></li><li><a class="nounderline abstract_t">Regueiro M, Feagan BG, Zou B, et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology 2016; 150:1568.</a></li><li><a class="nounderline abstract_t">Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136:441.</a></li><li><a class="nounderline abstract_t">Beelen EMJ, Nieboer D, Arkenbosch JHC, et al. Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. Clin Gastroenterol Hepatol 2022; 20:2741.</a></li><li><a class="nounderline abstract_t">Yoshida K, Fukunaga K, Ikeuchi H, et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis 2012; 18:1617.</a></li><li><a class="nounderline abstract_t">Aguas M, Bastida G, Cerrillo E, et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. World J Gastroenterol 2012; 18:4391.</a></li><li><a class="nounderline abstract_t">De Cruz P, Kamm MA, Hamilton AL, et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. Aliment Pharmacol Ther 2015; 42:867.</a></li><li><a class="nounderline abstract_t">Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence. Clin Gastroenterol Hepatol 2014; 12:1494.</a></li><li><a class="nounderline abstract_t">Savarino E, Bodini G, Dulbecco P, et al. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Am J Gastroenterol 2013; 108:1731.</a></li><li><a class="nounderline abstract_t">Papamichael K, Archavlis E, Lariou C, Mantzaris GJ. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. J Crohns Colitis 2012; 6:924.</a></li><li><a class="nounderline abstract_t">Takeshima F, Yoshikawa D, Higashi S, et al. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol 2016; 16:82.</a></li><li><a class="nounderline abstract_t">Kotze PG, Yamamoto T, Danese S, et al. Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database. J Crohns Colitis 2015; 9:541.</a></li><li><a class="nounderline abstract_t">Preda CM, Fulger LE, Negreanu L, et al. Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study. Rev Esp Enferm Dig 2016; 108:642.</a></li><li><a class="nounderline abstract_t">Gjuladin-Hellon T, Iheozor-Ejiofor Z, Gordon M, Akobeng AK. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2019; 8:CD010233.</a></li><li><a class="nounderline abstract_t">Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104:2089.</a></li><li><a class="nounderline abstract_t">D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135:1123.</a></li><li><a class="nounderline abstract_t">Herfarth HH, Katz JA, Hanauer SB, et al. Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis 2013; 19:1073.</a></li><li><a class="nounderline abstract_t">Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128:856.</a></li><li><a class="nounderline abstract_t">Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011; :CD008414.</a></li><li><a class="nounderline abstract_t">Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:617.</a></li><li><a class="nounderline abstract_t">Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003; 17:517.</a></li></ol></div><div id="topicVersionRevision">Topic 4084 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12809829" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15339320" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Systematic review: has disease outcome in Crohn's disease changed during the last four decades?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23896172" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25542619" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Surgery for Crohn's disease: look harder, act faster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840074" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9453485" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1681159" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22500519" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evaluation for postoperative recurrence of Crohn disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7768364" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10648454" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823987" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27928830" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2394349" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Predictability of the postoperative course of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568651" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25331349" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32692069" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445951" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14769308" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996018" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Factors affecting recurrence after surgery for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16760753" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Postoperative maintenance therapy for inflammatory bowel disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20010925" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18762954" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The effect of smoking after surgery for Crohn's disease: a meta-analysis of observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244543" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6884714" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Risk factors for postoperative recurrence of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9007626" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Factors affecting recurrence in Crohn's disease. Results of a prospective audit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8756849" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Factors influencing recurrence in Crohn's disease. An analysis of a consecutive series of 353 patients treated with primary surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7797122" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10636100" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Risk factors for surgery and postoperative recurrence in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840073" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : American Gastroenterological Association Institute Technical Review on the Management of Crohn's Disease After Surgical Resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17900320" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating versus nonperforating Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319461" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Risk factors regarding the need for a second operation in patients with Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12068198" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118641" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19229992" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recurrence patterns after first resection for stricturing or penetrating Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534633" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Surgical predictors of recurrence of Crohn's disease after ileocolonic resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11357022" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Recurrence after colectomy in Crohn's colitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27138979" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Is an Ounce of Prevention Worth a Pound of Cure: Postoperative Recurrence of Crohn's Disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25542620" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Crohn's disease management after intestinal resection: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18942739" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Postoperative therapy for Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27086006" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A Practical Approach to Preventing Postoperative Recurrence in Crohn's Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9394721" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11696286" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1914726" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Do microscopic abnormalities at resection margins correlate with increased anastomotic recurrence in Crohn's disease? Retrospective analysis of 100 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8646350" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Correlation between early recurrence and reoperation after ileocolonic resection in Crohn's disease: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21830279" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Postoperative recurrent luminal Crohn's disease: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16232020" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26946343" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19109962" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Infliximab prevents Crohn's disease recurrence after ileal resection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34687970" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22081474" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22969204" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26314275" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24440221" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Postoperative therapy with infliximab prevents long-term Crohn's disease recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019080" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424843" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27472988" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25820017" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for crohn's disease: results from the MULTIPER database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27651132" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425621" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19568226" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727929" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23511031" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15825069" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21249709" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21407190" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622760" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
